Roche Holding AG

SIX:ROG

Dr. Thomas Schinecker

Chief Executive Officer

Dr. Thomas Schinecker is a prominent figure in the pharmaceutical and diagnostics industry, currently serving as the CEO of Roche Holding AG, one of the world's leading healthcare companies. Schinecker has had a distinguished career at Roche, having joined the company in 2003. He holds a PhD in Molecular Biology from New York University and has accumulated extensive experience working in various capacities within Roche, particularly in the diagnostics division. Over his career at Roche, he has been instrumental in driving innovation and growth, particularly in the area of diagnostic testing, which has become increasingly crucial to the company’s portfolio. Under his leadership, Roche Diagnostics has achieved significant advancements, particularly in the development of tests critical for managing infectious diseases and cancer diagnostics. This was particularly notable during the COVID-19 pandemic, where the company played a pivotal role in developing and distributing PCR and antibody tests worldwide. Dr. Schinecker's tenure as CEO is marked by a continued focus on personalized healthcare, integrating advanced diagnostic solutions, and leveraging data-driven insights to enhance patient outcomes. His strategic vision aims to further solidify Roche's position at the forefront of health innovation, emphasizing sustainability, patient-centric approaches, and collaboration across the healthcare ecosystem.

Claudia Bockstiegel is a notable executive at Roche Holding AG, where she serves as the General Counsel. In this critical role, she oversees the company's legal strategies and ensures compliance with global regulations, leveraging her extensive experience in corporate law. Claudia holds a law degree from the University of Heidelberg in Germany and has a distinguished career in legal counseling, focusing on the biopharmaceutical industry. Her leadership in navigating complex legal landscapes supports Roche's mission in advancing healthcare solutions.

Pascale Schmidt is an executive at Roche Holding AG, a leading global healthcare company headquartered in Basel, Switzerland. She has held various roles within the organization, focusing on promoting innovation and driving strategic initiatives to advance Roche's mission in healthcare and pharmaceuticals. With a strong background in business and leadership, Pascale Schmidt contributes significantly to Roche's efforts in delivering pioneering medical solutions and maintaining its standing as a leader in the industry. Her work typically involves collaborating with diverse teams, overseeing projects aimed at improving patient outcomes, and enhancing the company's operational efficiency.

Cristina A. Wilbur is the Chief People Officer and a member of the Corporate Executive Committee at Roche Holding AG. In her role, she is responsible for leading the company's human resources strategy, focusing on talent management, organizational development, and fostering an inclusive company culture. Wilbur plays a critical role in shaping Roche's workforce to support innovation and growth in the healthcare sector. Her leadership in HR emphasizes employee engagement and development, aligning with Roche's mission to improve patient care worldwide. Prior to her current position, Wilbur has accumulated extensive experience in various HR and leadership roles across different industries.

Dr. Nicolas Dunant is a notable executive associated with Roche Holding AG, a global leader in pharmaceuticals and diagnostics. He has been a significant figure within the company, contributing to various innovative healthcare solutions. Dr. Dunant’s work primarily focuses on leveraging his scientific expertise and strategic acumen to advance Roche's mission of delivering groundbreaking medical advancements. With a deep background in life sciences, he is well-regarded for his leadership within the company and his ability to bridge scientific research with practical applications in medicine. Additionally, his efforts have often emphasized the importance of personalized healthcare, a core priority for Roche in adapting to the evolving landscape of healthcare needs.

Paulo Fontoura is a seasoned executive in the pharmaceutical industry, known for his significant contributions to Roche Holding AG. He serves as the Global Head of Neuroscience, Immunology, Ophthalmology, and Infectious Diseases Clinical Development at Roche. With a strong background in medical research and clinical development, Fontoura has played a pivotal role in advancing Roche's efforts in these crucial therapeutic areas. Under his leadership, the company has focused on innovative approaches to address complex medical challenges and unmet needs in these fields. His work ensures that Roche continues to make strides in delivering impactful and transformative therapies to patients worldwide. Fontoura's expertise and leadership are integral to Roche's mission of improving global health outcomes through groundbreaking science and research.

Dr. Johannes Carolus Clevers is an influential figure in the biomedical field and is associated with Roche Holding AG, a leading pharmaceutical and diagnostics company. He is widely recognized for his pioneering work in stem cell research and cancer biology. Dr. Clevers has achieved significant breakthroughs in understanding the molecular mechanisms governing the behavior of stem cells and their role in cancer progression. Dr. Clevers was born in the Netherlands and pursued a medical degree followed by a Ph.D., which laid a strong foundation for his future research endeavors. His career has been marked by a commitment to translating basic research into clinical applications, with a particular focus on colorectal cancer and the Wnt signaling pathway, which plays a critical role in the regulation of cell growth and differentiation. He is notable for his development of organoid technology, which involves growing mini-organs in vitro from stem cells. This technology has revolutionized biomedical research by providing more accurate models for studying disease and testing treatments, significantly impacting fields like regenerative medicine and personalized cancer therapy. Throughout his career, Dr. Clevers has held esteemed positions in both academia and industry, contributing to his reputation as a thought leader in life sciences. His work with Roche underscores the company's dedication to advancing medical research and innovation. Dr. Clevers' contributions have earned him numerous accolades and a strong presence in the scientific community globally.